Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2377040

N#CC1CCCNC1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.42
SLC6A11 P48066 1/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLC6A13 Q9NSD5 1/20 0.42
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
CYP2D6 P10635 1/20 0.37
IRAK4 Q9NWZ3 3/20 0.35
CPN1 P15169 2/20 0.34
CPB2 Q96IY4 2/20 0.34
DPP4 P27487 2/20 0.31
DPP8 Q6V1X1 2/20 0.31
CHRM3 P20309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2394605 1.00 SLC6A1 (0.42) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL31601844 0.90 SLC6A1 (0.35) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL2379448 0.90 SLC6A1 (0.35) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL2378662 0.90 SLC6A1 (0.35) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL17500734 0.82 SLC6A2 (0.32) CYP2D6DPP4DPP8
SCHEMBL12259738 0.82
SCHEMBL13632296 0.82
SCHEMBL1019673 0.82
Hydrochloric Acid SCHEMBL1972660 0.80
Hydrochloric Acid SCHEMBL26613851 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116964046-B PLK4 inhibitors and uses thereof 上海齐鲁制药研究中心有限公司 2024-04-19 CN disclosed
CN-116964046-A PLK4 inhibitors and uses thereof 上海齐鲁制药研究中心有限公司 2023-10-27 CN disclosed
WO-2022184049-A1 PLK4 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2022-09-09 WO disclosed
US-8518945-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-08-27 US disclosed
EP-2550273-A2 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2013-01-30 EP disclosed
WO-2011117145-A2 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-29 WO disclosed
US-20110230462-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230462-A1 Pyrrolopyrazine Kinase Inhibitors SYK, ZAP70, BTK SLC6A1 4859/4885SLC6A11 4854/4885TSHR 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.